Cost‐effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea-Reference-Cited by-同舟云学术

Cost‐effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea

Published:2018-12-25 Issue:4 Volume:34 Page:776-783
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Chung Wankyo¹,Kim Kyung‐Ah²,Jang Eun Sun³,Ki Moran⁴,Choi Hwa Young⁴,Jeong Sook‐Hyang³

Affiliation:

1. Department of Public Health Science and Institute of Health and Environment, Graduate School of Public HealthSeoul National University Seoul Korea

2. Department of Internal MedicineInje University Ilsan Paik Hospital Goyang Gyeonggi Korea

3. Department of Internal Medicine, Seoul National University College of MedicineSeoul National University Bundang Hospital Seongnam Gyeonggi Korea

4. Department of Cancer Control and Population Health, Graduate School of Cancer Science and PolicyNational Cancer Center Goyang Gyeonggi Korea

Funder

Korea Health Technology R&D Project

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.14554

Reference31 articles.

1. World Health Organization.Global hepatitis report 2017. Paris France 2017. Available from:http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455‐eng.pdf?ua=1.

2. A nationwide seroepidemiology of hepatitis C virus infection in South Korea

3. Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study

4. The clinical outcomes of chronic hepatitis C in South Korea

5. Efficacy and Tolerability of Pegylated Interferon-α_2a plus Ribavirin versus Pegylated Interferon-α_2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients